TY  - JOUR
AU  - Pavlov-Dolijanović, Slavica
AU  - Vujasinović-Stupar, Nada
AU  - Zugić, Vladimir
AU  - Ostojić, Predrag
AU  - Zeković, Ana
AU  - Živanović-Radnić, Tatjana
AU  - Jeremić, Ivan
AU  - Tadić, Ivana
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3066
AB  - The study aims to analyze the effects of induction treatment with cyclophosphamide (CYC) pulse therapy followed by maintenance treatment with other mild immunosuppressive agents on lung function in scleroderma (SSc) patients. Thirty patients with SSc (mean age 52years, mean disease duration  lt 2years) with forced vital capacity (FVC) 80% and/or diffusing capacity of carbon monoxide (DLco) 70% were included. Monthly CYC pulses were given for 6months (induction treatment), followed by 3-monthly maintenance pulses for the next 18months, and during the next 5years patients received other mild immunosupressive therapy brought by the competent rheumatologist. The efficacy was evaluated by comparing FVC% and DLco% after 6, 24, and 84months from the baseline. All patients completed induction and maintenance treatment with CYC. Three patients were lost to follow-up. The rest of 27 patients, during the next 5years, received other immunosupressive agents (14 azathioprine, 9 methotrexate, and 4 mycophenolate mofetil). Three patients died in the 4years of follow-up. By 6, 24, and 84months, the mean FVC and DLco changes were +0.47 and +2.10, +3.30 and -2.49, and +1.53 and -3.76%, respectively. These changes were not significantly different from the baseline values. CYC does not appear to result in clinically significant improvement of pulmonary function but fulfilled criteria of stable disease. Maintenance treatment with other mild immunosupressive agents preserves the benefits achieved during CYC treatment.
PB  - Springer
T2  - Clinical Rheumatology
T1  - Long-term effects of immunosuppressive therapy on lung function in scleroderma patients
VL  - 37
IS  - 11
SP  - 3043
EP  - 3050
DO  - 10.1007/s10067-018-4266-0
ER  - 

@article{
author = "Pavlov-Dolijanović, Slavica and Vujasinović-Stupar, Nada and Zugić, Vladimir and Ostojić, Predrag and Zeković, Ana and Živanović-Radnić, Tatjana and Jeremić, Ivan and Tadić, Ivana",
year = "2018",
abstract = "The study aims to analyze the effects of induction treatment with cyclophosphamide (CYC) pulse therapy followed by maintenance treatment with other mild immunosuppressive agents on lung function in scleroderma (SSc) patients. Thirty patients with SSc (mean age 52years, mean disease duration  lt 2years) with forced vital capacity (FVC) 80% and/or diffusing capacity of carbon monoxide (DLco) 70% were included. Monthly CYC pulses were given for 6months (induction treatment), followed by 3-monthly maintenance pulses for the next 18months, and during the next 5years patients received other mild immunosupressive therapy brought by the competent rheumatologist. The efficacy was evaluated by comparing FVC% and DLco% after 6, 24, and 84months from the baseline. All patients completed induction and maintenance treatment with CYC. Three patients were lost to follow-up. The rest of 27 patients, during the next 5years, received other immunosupressive agents (14 azathioprine, 9 methotrexate, and 4 mycophenolate mofetil). Three patients died in the 4years of follow-up. By 6, 24, and 84months, the mean FVC and DLco changes were +0.47 and +2.10, +3.30 and -2.49, and +1.53 and -3.76%, respectively. These changes were not significantly different from the baseline values. CYC does not appear to result in clinically significant improvement of pulmonary function but fulfilled criteria of stable disease. Maintenance treatment with other mild immunosupressive agents preserves the benefits achieved during CYC treatment.",
publisher = "Springer",
journal = "Clinical Rheumatology",
title = "Long-term effects of immunosuppressive therapy on lung function in scleroderma patients",
volume = "37",
number = "11",
pages = "3043-3050",
doi = "10.1007/s10067-018-4266-0"
}

Pavlov-Dolijanović, S., Vujasinović-Stupar, N., Zugić, V., Ostojić, P., Zeković, A., Živanović-Radnić, T., Jeremić, I.,& Tadić, I.. (2018). Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. in Clinical Rheumatology
Springer., 37(11), 3043-3050.
https://doi.org/10.1007/s10067-018-4266-0

Pavlov-Dolijanović S, Vujasinović-Stupar N, Zugić V, Ostojić P, Zeković A, Živanović-Radnić T, Jeremić I, Tadić I. Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. in Clinical Rheumatology. 2018;37(11):3043-3050.
doi:10.1007/s10067-018-4266-0 .

Pavlov-Dolijanović, Slavica, Vujasinović-Stupar, Nada, Zugić, Vladimir, Ostojić, Predrag, Zeković, Ana, Živanović-Radnić, Tatjana, Jeremić, Ivan, Tadić, Ivana, "Long-term effects of immunosuppressive therapy on lung function in scleroderma patients" in Clinical Rheumatology, 37, no. 11 (2018):3043-3050,
https://doi.org/10.1007/s10067-018-4266-0 . .

TY  - JOUR
AU  - Vujasinović-Stupar, Nada
AU  - Radojčić, Ljiljana
AU  - Tadić, Ivana
AU  - Pavlov-Dolijanović, Slavica
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2945
AB  - Background/Aim. Osteoporosis mainly affects women in the early years following menopause. The aim of this study was to determine the level of knowledge about osteoporosis and osteoporosis related risk factors in postmenopausal women in Serbia. Methods. The study included postmenopausal women regardless if suffering from osteoporosis or not. Assessment of knowledge was carried out by using the Osteoporosis Knowledge Assessment Tool - Shorter Version (OKAT-S) questionnaire that was validated for Serbian population. Answers to the 9 questions were coded as 1 - true, or 0 - false or 'do not know'. Also, the following risk factors data for osteoporosis were collected: age, the onset and duration of menopause, body mass index (BMI), data on fractures, the incidence of falls, smoking, lifestyle (active, sedentary), regular sunbathing, calcium and vitamin D supplementation, intake of milk and dairy products. Results. A total of 132 postmenopausal women responded to the questionnaire with the response rate of 90.41%. Their knowledge varied from 27.94% to 74.26% of the correct answers, with the average OKAT-S score of 4.5 (SD = 2.55), which was 50% of the maximum possible score. Only 2 participants (1.47%) filled the all OKAT-S items correctly, while 11 (8.09%) of them did not have the proper answer to any question. A reduced bone density (T-score below -1) was registered in 40.91% of the women, previous fractures in 49 (34.51%), and more or less 3 falls registered in 9.59% or 4.79%, respectively. Conclusion. The Serbian version of the questionnaire OKAT-S revealed generally poor knowledge on osteoporosis among postmenopausal women in Serbia. Developing effective interventions and public health programms could be helpful in general education towards understanding osteoporosis and risk factors. Promotion of preventive measures and healthy behaviour may prevent or at least slow down the accelerated bone loss in postmenopausal women.
AB  - Uvod/Cilj. Osteoporoza uglavnom pogađa žene u ranim godinama posle menopauze. Cilj rada bio je da se proceni znanje o osteoporozi i faktorima rizika kod žena u postmenopauzi u Srbiji. Metode. U studiju su bile uključene žene u postmenopauzi nezavisno od toga da li boluju od osteoporoze ili ne. Procena znanja o osteoporozi vršena je pomoću upitnika Osteoporosis Knowledge Assessment Tool - Shorter Version (OKAT-S) koji je validiran za srpsku populaciju. Odgovori na 9 pitanja kodirani su sa 1 - pravilan ili 0 - nepravilan odgovor ili 'ne znam'. Takođe, sakupljeni su sledeći podaci o faktorima rizika od osteoporoze: starost, početak i dužina trajanja menopauze, indeks telesne mase [body mass index (BMI)], podaci o prelomima, broj padova, pušenje, životni stil (sedeći ili aktivni), redovno sunčanje, dopuna kalcijumom i vitaminom D, korišćenje mleka i mlečnih proizvoda. Rezultati. Od ukupno 146 ispitanica, upitnik OKAT-S popunile su 132 ispitanice (nivo odgovora od 90,41%). Nivo njihovog znanja varirao je od 27,94% do 74,26% ispravnih odgovora, sa prosečnim OKAT-S skorom od 4,5 (SD = 2,55), što čini 50% od maksimalno mogućeg skora. Samo dve ispitanice (1,47%) pravilno su odgovorile na sva pitanja, dok njih 11 (8,09%) nije imalo nijedan ispravan odgovor. Snižen T-skor, manje od -1, registrovan je kod 40,91% ispitanica, a prethodni prelom kod 49 (34,51%). Kod 9,59% ispitanica registrovano je više od 3, a kod 4,79% manje od 3 pada. Zaključak. Srpska verzija upitnika OKAT-S otkrila je generalno loše znanje o osteoporozi kod žena u postmenopauzi u Srbiji. Poboljšano znanje o osteoporozi i faktorima rizika moguće je postići razvojem efikasnih interventnih i javnih zdravstvenih programa. Promocija preventivnih mera i zdravog ponašanja može sprečiti ili bar usporiti prerani gubitak koštane mase kod žena u postmenopauzi.
PB  - Vojnomedicinska akademija - Institut za naučne informacije, Beograd
T2  - Vojnosanitetski pregled
T1  - Osteoporosis-related knowledge among Serbian postmenopausal women
T1  - Znanje o osteoporozi kod žena u postmenopauzi u Srbiji
VL  - 74
IS  - 5
SP  - 445
EP  - 449
DO  - 10.2298/VSP150716107V
ER  - 

@article{
author = "Vujasinović-Stupar, Nada and Radojčić, Ljiljana and Tadić, Ivana and Pavlov-Dolijanović, Slavica",
year = "2017",
abstract = "Background/Aim. Osteoporosis mainly affects women in the early years following menopause. The aim of this study was to determine the level of knowledge about osteoporosis and osteoporosis related risk factors in postmenopausal women in Serbia. Methods. The study included postmenopausal women regardless if suffering from osteoporosis or not. Assessment of knowledge was carried out by using the Osteoporosis Knowledge Assessment Tool - Shorter Version (OKAT-S) questionnaire that was validated for Serbian population. Answers to the 9 questions were coded as 1 - true, or 0 - false or 'do not know'. Also, the following risk factors data for osteoporosis were collected: age, the onset and duration of menopause, body mass index (BMI), data on fractures, the incidence of falls, smoking, lifestyle (active, sedentary), regular sunbathing, calcium and vitamin D supplementation, intake of milk and dairy products. Results. A total of 132 postmenopausal women responded to the questionnaire with the response rate of 90.41%. Their knowledge varied from 27.94% to 74.26% of the correct answers, with the average OKAT-S score of 4.5 (SD = 2.55), which was 50% of the maximum possible score. Only 2 participants (1.47%) filled the all OKAT-S items correctly, while 11 (8.09%) of them did not have the proper answer to any question. A reduced bone density (T-score below -1) was registered in 40.91% of the women, previous fractures in 49 (34.51%), and more or less 3 falls registered in 9.59% or 4.79%, respectively. Conclusion. The Serbian version of the questionnaire OKAT-S revealed generally poor knowledge on osteoporosis among postmenopausal women in Serbia. Developing effective interventions and public health programms could be helpful in general education towards understanding osteoporosis and risk factors. Promotion of preventive measures and healthy behaviour may prevent or at least slow down the accelerated bone loss in postmenopausal women., Uvod/Cilj. Osteoporoza uglavnom pogađa žene u ranim godinama posle menopauze. Cilj rada bio je da se proceni znanje o osteoporozi i faktorima rizika kod žena u postmenopauzi u Srbiji. Metode. U studiju su bile uključene žene u postmenopauzi nezavisno od toga da li boluju od osteoporoze ili ne. Procena znanja o osteoporozi vršena je pomoću upitnika Osteoporosis Knowledge Assessment Tool - Shorter Version (OKAT-S) koji je validiran za srpsku populaciju. Odgovori na 9 pitanja kodirani su sa 1 - pravilan ili 0 - nepravilan odgovor ili 'ne znam'. Takođe, sakupljeni su sledeći podaci o faktorima rizika od osteoporoze: starost, početak i dužina trajanja menopauze, indeks telesne mase [body mass index (BMI)], podaci o prelomima, broj padova, pušenje, životni stil (sedeći ili aktivni), redovno sunčanje, dopuna kalcijumom i vitaminom D, korišćenje mleka i mlečnih proizvoda. Rezultati. Od ukupno 146 ispitanica, upitnik OKAT-S popunile su 132 ispitanice (nivo odgovora od 90,41%). Nivo njihovog znanja varirao je od 27,94% do 74,26% ispravnih odgovora, sa prosečnim OKAT-S skorom od 4,5 (SD = 2,55), što čini 50% od maksimalno mogućeg skora. Samo dve ispitanice (1,47%) pravilno su odgovorile na sva pitanja, dok njih 11 (8,09%) nije imalo nijedan ispravan odgovor. Snižen T-skor, manje od -1, registrovan je kod 40,91% ispitanica, a prethodni prelom kod 49 (34,51%). Kod 9,59% ispitanica registrovano je više od 3, a kod 4,79% manje od 3 pada. Zaključak. Srpska verzija upitnika OKAT-S otkrila je generalno loše znanje o osteoporozi kod žena u postmenopauzi u Srbiji. Poboljšano znanje o osteoporozi i faktorima rizika moguće je postići razvojem efikasnih interventnih i javnih zdravstvenih programa. Promocija preventivnih mera i zdravog ponašanja može sprečiti ili bar usporiti prerani gubitak koštane mase kod žena u postmenopauzi.",
publisher = "Vojnomedicinska akademija - Institut za naučne informacije, Beograd",
journal = "Vojnosanitetski pregled",
title = "Osteoporosis-related knowledge among Serbian postmenopausal women, Znanje o osteoporozi kod žena u postmenopauzi u Srbiji",
volume = "74",
number = "5",
pages = "445-449",
doi = "10.2298/VSP150716107V"
}

Vujasinović-Stupar, N., Radojčić, L., Tadić, I.,& Pavlov-Dolijanović, S.. (2017). Osteoporosis-related knowledge among Serbian postmenopausal women. in Vojnosanitetski pregled
Vojnomedicinska akademija - Institut za naučne informacije, Beograd., 74(5), 445-449.
https://doi.org/10.2298/VSP150716107V

Vujasinović-Stupar N, Radojčić L, Tadić I, Pavlov-Dolijanović S. Osteoporosis-related knowledge among Serbian postmenopausal women. in Vojnosanitetski pregled. 2017;74(5):445-449.
doi:10.2298/VSP150716107V .

Vujasinović-Stupar, Nada, Radojčić, Ljiljana, Tadić, Ivana, Pavlov-Dolijanović, Slavica, "Osteoporosis-related knowledge among Serbian postmenopausal women" in Vojnosanitetski pregled, 74, no. 5 (2017):445-449,
https://doi.org/10.2298/VSP150716107V . .

TY  - CONF
AU  - Tasić, Ljiljana
AU  - Vujasinović-Stupar, Nada
AU  - Arsić, Tanja
AU  - Dimić, Aleksandar
AU  - Matić, Branislava
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2418
PB  - Springer, Dordrecht
C3  - International Journal of Clinical Pharmacy
T1  - Attitudes of patients and pharmacists about the community pharmacy service of prevention and treatment of osteoporosis
VL  - 37
IS  - 2
SP  - 416
EP  - 417
DO  - 10.1007/s11096-015-0080-9
ER  - 

@conference{
author = "Tasić, Ljiljana and Vujasinović-Stupar, Nada and Arsić, Tanja and Dimić, Aleksandar and Matić, Branislava",
year = "2015",
publisher = "Springer, Dordrecht",
journal = "International Journal of Clinical Pharmacy",
title = "Attitudes of patients and pharmacists about the community pharmacy service of prevention and treatment of osteoporosis",
volume = "37",
number = "2",
pages = "416-417",
doi = "10.1007/s11096-015-0080-9"
}

Tasić, L., Vujasinović-Stupar, N., Arsić, T., Dimić, A.,& Matić, B.. (2015). Attitudes of patients and pharmacists about the community pharmacy service of prevention and treatment of osteoporosis. in International Journal of Clinical Pharmacy
Springer, Dordrecht., 37(2), 416-417.
https://doi.org/10.1007/s11096-015-0080-9

Tasić L, Vujasinović-Stupar N, Arsić T, Dimić A, Matić B. Attitudes of patients and pharmacists about the community pharmacy service of prevention and treatment of osteoporosis. in International Journal of Clinical Pharmacy. 2015;37(2):416-417.
doi:10.1007/s11096-015-0080-9 .

Tasić, Ljiljana, Vujasinović-Stupar, Nada, Arsić, Tanja, Dimić, Aleksandar, Matić, Branislava, "Attitudes of patients and pharmacists about the community pharmacy service of prevention and treatment of osteoporosis" in International Journal of Clinical Pharmacy, 37, no. 2 (2015):416-417,
https://doi.org/10.1007/s11096-015-0080-9 . .

TY  - CONF
AU  - Tadić, Ivana
AU  - Vujasinović-Stupar, Nada
AU  - Pavlov-Dolijanović, Slavica
AU  - Baltić, S.
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2338
PB  - Springer
C3  - Osteoporosis International
T1  - The illness perception and adherence of osteoporosis patients
VL  - 26, Suppl. 1
SP  - S347
EP  - S-347
DO  - 10.1007/s00198-015-3068-3
ER  - 

@conference{
author = "Tadić, Ivana and Vujasinović-Stupar, Nada and Pavlov-Dolijanović, Slavica and Baltić, S.",
year = "2015",
publisher = "Springer",
journal = "Osteoporosis International",
title = "The illness perception and adherence of osteoporosis patients",
volume = "26, Suppl. 1",
pages = "S347-S-347",
doi = "10.1007/s00198-015-3068-3"
}

Tadić, I., Vujasinović-Stupar, N., Pavlov-Dolijanović, S.,& Baltić, S.. (2015). The illness perception and adherence of osteoporosis patients. in Osteoporosis International
Springer., 26, Suppl. 1, S347-S-347.
https://doi.org/10.1007/s00198-015-3068-3

Tadić I, Vujasinović-Stupar N, Pavlov-Dolijanović S, Baltić S. The illness perception and adherence of osteoporosis patients. in Osteoporosis International. 2015;26, Suppl. 1:S347-S-347.
doi:10.1007/s00198-015-3068-3 .

Tadić, Ivana, Vujasinović-Stupar, Nada, Pavlov-Dolijanović, Slavica, Baltić, S., "The illness perception and adherence of osteoporosis patients" in Osteoporosis International, 26, Suppl. 1 (2015):S347-S-347,
https://doi.org/10.1007/s00198-015-3068-3 . .

TY  - JOUR
AU  - Tadić, Ivana
AU  - Tasić, Ljiljana
AU  - Vujasinović-Stupar, Nada
AU  - Ilić, Katarina
AU  - Stevanović, Dejan
PY  - 2014
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2241
AB  - Osteoporosis is a chronic disease with increasing incidence that predominantly occurs in female population. There are evidences that bisphosphonates, selective estrogen receptor modulators, denosumab, teriparatide and strontium renalate, prevent vertebral fractures while alendronate, risedronate, zoledronic acid, denosumab and strontium renalate prevent hip fractures. Although these drugs are effective in osteoporosis treatment, their use is limited by their side-effects and low-adherence. The aim of this review article was to compare efficacy of new drugs for osteoporosis currently in phase 2 and 3 clinical trials. After reviewing 57 articles available on PubMed and Scopus databases that evaluated efficacy of osteoporosis medications, 10 papers, that fulfilled the review criteria, were selected for the analysis. Finally, the efficacy of five drugs was compared. Efficacy was evaluated by the values of bone mineral density (BMD) and bone turnover markers (BTM). In all the analyzed articles the BMD increased and changes of BTM were noted. The highest increase of lumbar BMD from the baseline values was achieved after six months of subcutaneous application of 20 μg/day teriparatide (11.3%). The lowest increase of BMD in the same region was recorded after six months of risedronate therapy 100 mg per os once monthly (2.1%). From ten selected articles, only one has reported data about fracture risk.
AB  - Osteoporoza je hronična bolest koja je sve više zastupljena i to pretežno kod osoba ženskog pola. Postoje dokazi da bisfosfonati, selektivni modulatori estrogenskih receptora, denosumab, teriparatid i stroncijum ranelat mogu da preveniraju prelom kuka. Iako su ovi lekovi efikasni u lečenju osteoporoze, njihova upotreba je ograničena usled ispoljavanja neželjenih reakcija, a time i postojanja niske adherencije bolesnika. Cilj ovog preglednog rada bio je upoređivanje efikasnosti novih lekova za lečenje osteoporoze koji su trenutno u 2. i 3. fazi kliničkih istraživanja. Nakon pregleda 57 originalnih radova koji su imali za cilj da pokažu efikasnost lekova u lečenju osteoporoze, dostupnih na PubMed i Scopus bazi, za analizu je odabrano 10 radova koji su zadovoljili kriterijume za pretraživanje. Na kraju analize, poređena je efikasnost pet lekova. Efikasnost je evaluirana na osnovu vrednosti mineralne koštane gustine (BMD) i koštanih markera (BTM). Povećanje BMD vrednosti i promene u vrednostima BTM zabeležene su u svim radovima. Najveće povećanje BMD (za 11,3%) lumbalnog skeletnog regiona postignuto je nakon šestomesečne subkutane terapije teriparatidom u dozi 20 μg dnevno. Najmanje povećanje BMD (za 2,1%) istog skeletnog regiona zabeleženo je nakon šestomesečne per os terapije risedronatom u dozi od 100 mg jednom mesečno. Od deset analiziranih studija, samo je jedna prikazala podatke o riziku od frakture.
PB  - Univerzitet u Nišu - Medicinski fakultet, Niš
T2  - Acta Facultatis Medicae Naissensis
T1  - New drugs for osteoporosis therapy: A review of the clinical trials phase 2 and 3
T1  - Novi lekovi u terapiji osteoporoze - pregled 2. i 3. - faze kliničkih istraživanja
VL  - 31
IS  - 1
SP  - 29
EP  - 39
DO  - 10.2478/afmnai-2014-0003
ER  - 

@article{
author = "Tadić, Ivana and Tasić, Ljiljana and Vujasinović-Stupar, Nada and Ilić, Katarina and Stevanović, Dejan",
year = "2014",
abstract = "Osteoporosis is a chronic disease with increasing incidence that predominantly occurs in female population. There are evidences that bisphosphonates, selective estrogen receptor modulators, denosumab, teriparatide and strontium renalate, prevent vertebral fractures while alendronate, risedronate, zoledronic acid, denosumab and strontium renalate prevent hip fractures. Although these drugs are effective in osteoporosis treatment, their use is limited by their side-effects and low-adherence. The aim of this review article was to compare efficacy of new drugs for osteoporosis currently in phase 2 and 3 clinical trials. After reviewing 57 articles available on PubMed and Scopus databases that evaluated efficacy of osteoporosis medications, 10 papers, that fulfilled the review criteria, were selected for the analysis. Finally, the efficacy of five drugs was compared. Efficacy was evaluated by the values of bone mineral density (BMD) and bone turnover markers (BTM). In all the analyzed articles the BMD increased and changes of BTM were noted. The highest increase of lumbar BMD from the baseline values was achieved after six months of subcutaneous application of 20 μg/day teriparatide (11.3%). The lowest increase of BMD in the same region was recorded after six months of risedronate therapy 100 mg per os once monthly (2.1%). From ten selected articles, only one has reported data about fracture risk., Osteoporoza je hronična bolest koja je sve više zastupljena i to pretežno kod osoba ženskog pola. Postoje dokazi da bisfosfonati, selektivni modulatori estrogenskih receptora, denosumab, teriparatid i stroncijum ranelat mogu da preveniraju prelom kuka. Iako su ovi lekovi efikasni u lečenju osteoporoze, njihova upotreba je ograničena usled ispoljavanja neželjenih reakcija, a time i postojanja niske adherencije bolesnika. Cilj ovog preglednog rada bio je upoređivanje efikasnosti novih lekova za lečenje osteoporoze koji su trenutno u 2. i 3. fazi kliničkih istraživanja. Nakon pregleda 57 originalnih radova koji su imali za cilj da pokažu efikasnost lekova u lečenju osteoporoze, dostupnih na PubMed i Scopus bazi, za analizu je odabrano 10 radova koji su zadovoljili kriterijume za pretraživanje. Na kraju analize, poređena je efikasnost pet lekova. Efikasnost je evaluirana na osnovu vrednosti mineralne koštane gustine (BMD) i koštanih markera (BTM). Povećanje BMD vrednosti i promene u vrednostima BTM zabeležene su u svim radovima. Najveće povećanje BMD (za 11,3%) lumbalnog skeletnog regiona postignuto je nakon šestomesečne subkutane terapije teriparatidom u dozi 20 μg dnevno. Najmanje povećanje BMD (za 2,1%) istog skeletnog regiona zabeleženo je nakon šestomesečne per os terapije risedronatom u dozi od 100 mg jednom mesečno. Od deset analiziranih studija, samo je jedna prikazala podatke o riziku od frakture.",
publisher = "Univerzitet u Nišu - Medicinski fakultet, Niš",
journal = "Acta Facultatis Medicae Naissensis",
title = "New drugs for osteoporosis therapy: A review of the clinical trials phase 2 and 3, Novi lekovi u terapiji osteoporoze - pregled 2. i 3. - faze kliničkih istraživanja",
volume = "31",
number = "1",
pages = "29-39",
doi = "10.2478/afmnai-2014-0003"
}

Tadić, I., Tasić, L., Vujasinović-Stupar, N., Ilić, K.,& Stevanović, D.. (2014). New drugs for osteoporosis therapy: A review of the clinical trials phase 2 and 3. in Acta Facultatis Medicae Naissensis
Univerzitet u Nišu - Medicinski fakultet, Niš., 31(1), 29-39.
https://doi.org/10.2478/afmnai-2014-0003

Tadić I, Tasić L, Vujasinović-Stupar N, Ilić K, Stevanović D. New drugs for osteoporosis therapy: A review of the clinical trials phase 2 and 3. in Acta Facultatis Medicae Naissensis. 2014;31(1):29-39.
doi:10.2478/afmnai-2014-0003 .

Tadić, Ivana, Tasić, Ljiljana, Vujasinović-Stupar, Nada, Ilić, Katarina, Stevanović, Dejan, "New drugs for osteoporosis therapy: A review of the clinical trials phase 2 and 3" in Acta Facultatis Medicae Naissensis, 31, no. 1 (2014):29-39,
https://doi.org/10.2478/afmnai-2014-0003 . .

TY  - CONF
AU  - Tadić, Ivana
AU  - Vujasinović-Stupar, Nada
AU  - Tasić, Ljiljana
AU  - Stevanović, Dejan
AU  - Dimić, A.
AU  - Stamenković, Bojana
AU  - Stojanović, S.
AU  - Milenković, S.
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1985
AB  - OBJECTIVES: International Osteoporosis Foundation Quality of Life questionnaire
(QUALEFFO-41) is the specific questionnaire for the postmenopausal women
with osteoporosis and vertebral fractures. Reliability of the questionnaire could
be confirmed by sensitivity and specificity. The objective of this stidy is to test
the sensitivity and specificity of the QUALEFFO-41 questionnaire. METHODS: A
case-control study was conducted during the period of June 2010 - October 2011
to test the main characteristics of the questionnaire. The study included 100
patients with osteoporosis (50 cases with vertebral fractures and 50 controls
without fractures). The questionnaire EQ-5D (with direct-scoring) was used for
comparison of the results with the QUALEFFO-41 (with reverse-scoring). The
study was performed in two medical centers in Serbia. RESULTS: The results of
the ROC curve analysis (between the case and control group of patients)
indicated that the AUC ranges for all five dimensions of the QUALEFFO-41
questionnaire and the total score were 0.62–0.69. The QUALEFFO-41 had a better
prediction of the value of HRQOL of cases compared to the generic questionnaire
EQ-5D (the AUC difference of the total scores was 0.099, p=0.013). Correlations
between the total scores of the QUALEFFO-41 and the EQ-5D health state value,
for both groups, were negative and statistically significant (r=-0.78, p<0.001 and r
= -0.73, p<0.001, respectively). CONCLUSIONS: The QUALEFFO-41 has the ability
to detect the patients with osteoporosis and vertebral fractures among the
osteoporosis patients. This questionnaire is more specific for the osteoporosis
patients with fractures in relation to the EQ-5D questionnaire.
PB  - Elsevier Inc.
C3  - Value in Health
T1  - Sensitivity and specificity of a quality of life questionnaire qualeffo-41
VL  - 16
IS  - 3
SP  - A228
EP  - A228
DO  - 10.1016/j.jval.2013.03.1156
ER  - 

@conference{
author = "Tadić, Ivana and Vujasinović-Stupar, Nada and Tasić, Ljiljana and Stevanović, Dejan and Dimić, A. and Stamenković, Bojana and Stojanović, S. and Milenković, S.",
year = "2013",
abstract = "OBJECTIVES: International Osteoporosis Foundation Quality of Life questionnaire
(QUALEFFO-41) is the specific questionnaire for the postmenopausal women
with osteoporosis and vertebral fractures. Reliability of the questionnaire could
be confirmed by sensitivity and specificity. The objective of this stidy is to test
the sensitivity and specificity of the QUALEFFO-41 questionnaire. METHODS: A
case-control study was conducted during the period of June 2010 - October 2011
to test the main characteristics of the questionnaire. The study included 100
patients with osteoporosis (50 cases with vertebral fractures and 50 controls
without fractures). The questionnaire EQ-5D (with direct-scoring) was used for
comparison of the results with the QUALEFFO-41 (with reverse-scoring). The
study was performed in two medical centers in Serbia. RESULTS: The results of
the ROC curve analysis (between the case and control group of patients)
indicated that the AUC ranges for all five dimensions of the QUALEFFO-41
questionnaire and the total score were 0.62–0.69. The QUALEFFO-41 had a better
prediction of the value of HRQOL of cases compared to the generic questionnaire
EQ-5D (the AUC difference of the total scores was 0.099, p=0.013). Correlations
between the total scores of the QUALEFFO-41 and the EQ-5D health state value,
for both groups, were negative and statistically significant (r=-0.78, p<0.001 and r
= -0.73, p<0.001, respectively). CONCLUSIONS: The QUALEFFO-41 has the ability
to detect the patients with osteoporosis and vertebral fractures among the
osteoporosis patients. This questionnaire is more specific for the osteoporosis
patients with fractures in relation to the EQ-5D questionnaire.",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "Sensitivity and specificity of a quality of life questionnaire qualeffo-41",
volume = "16",
number = "3",
pages = "A228-A228",
doi = "10.1016/j.jval.2013.03.1156"
}

Tadić, I., Vujasinović-Stupar, N., Tasić, L., Stevanović, D., Dimić, A., Stamenković, B., Stojanović, S.,& Milenković, S.. (2013). Sensitivity and specificity of a quality of life questionnaire qualeffo-41. in Value in Health
Elsevier Inc.., 16(3), A228-A228.
https://doi.org/10.1016/j.jval.2013.03.1156

Tadić I, Vujasinović-Stupar N, Tasić L, Stevanović D, Dimić A, Stamenković B, Stojanović S, Milenković S. Sensitivity and specificity of a quality of life questionnaire qualeffo-41. in Value in Health. 2013;16(3):A228-A228.
doi:10.1016/j.jval.2013.03.1156 .

Tadić, Ivana, Vujasinović-Stupar, Nada, Tasić, Ljiljana, Stevanović, Dejan, Dimić, A., Stamenković, Bojana, Stojanović, S., Milenković, S., "Sensitivity and specificity of a quality of life questionnaire qualeffo-41" in Value in Health, 16, no. 3 (2013):A228-A228,
https://doi.org/10.1016/j.jval.2013.03.1156 . .

TY  - CONF
AU  - Tadić, Ivana
AU  - Lakić, Dragana
AU  - Odalović, Marina
AU  - Tasić, Ljiljana
AU  - Vujasinović-Stupar, Nada
AU  - Stevanović, Dejan
AU  - Petrova, Guenka
AU  - Krajnović, Dušanka
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1921
AB  - Oobjectives: Osteoporosis is a chronic disease which has impact on specific
aspects of health such as pain, physical functioning, social and mental functioning
and loss of personal independence. Generic questionnaire EQ-5D explores similar
dimensions and therefore is usually used as a questionnaire for assessing the con-
current validity of the specific osteoporosis questionnaires. The objective of this
study was to explore for a potential correlation between the similar dimensions
of the specific osteoporosis questionnaire QUALEFFO-41 and EQ-5D. Methods:
Analyzed data were a part of the study that included 50 patients with osteoporosis
and vertebral fractures conducted during the period June 2010 - October 2011.
The correlation between the questionnaires was assessed using the Spearman’s
correlation coefficient. Results: Strong correlations were found between EQ-5D
index / VAS score and QUALEFFO-41 total score (ρ = -0.73 and ρ = -0.57, p< 0.001,
respectively). The EQ-5D dimensions “Pain/discomfort”, “Mobility”, “Activities”,
“Anxiety/Depression” similar to QUALEFFO-41 dimensions “Pain”, “Physical func-
tion”, “Leisure, social activities”, “Mental function” were also strongly correlated
(ρ = 0.42, ρ = 0.76, ρ = 0.46 and ρ = 0.32, p< 0.001, respectively). ConClusions: Strong
correlations between similar dimensions of the compared questionnaires were
notified. Negative values of the Spearman’s correlation coefficient indicated that
total score of the QUALEFFO-41 were scored in the reverse order. There was only
one QUALEFFO-41 dimension (“General health perception”) that is not similar to
any of the EQ-5D dimensions. Although there was a strong correlation between
the total scores of compared questionnaires, the results of the EQ-5D question-
naire should be observed with caution, because it does not contain all important
dimensions that osteoporosis affects
PB  - Elsevier Inc.
C3  - Value in Health
T1  - Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?
VL  - 16
IS  - 7
SP  - A601
EP  - A601
DO  - 10.1016/j.jval.2013.08.1704
ER  - 

@conference{
author = "Tadić, Ivana and Lakić, Dragana and Odalović, Marina and Tasić, Ljiljana and Vujasinović-Stupar, Nada and Stevanović, Dejan and Petrova, Guenka and Krajnović, Dušanka",
year = "2013",
abstract = "Oobjectives: Osteoporosis is a chronic disease which has impact on specific
aspects of health such as pain, physical functioning, social and mental functioning
and loss of personal independence. Generic questionnaire EQ-5D explores similar
dimensions and therefore is usually used as a questionnaire for assessing the con-
current validity of the specific osteoporosis questionnaires. The objective of this
study was to explore for a potential correlation between the similar dimensions
of the specific osteoporosis questionnaire QUALEFFO-41 and EQ-5D. Methods:
Analyzed data were a part of the study that included 50 patients with osteoporosis
and vertebral fractures conducted during the period June 2010 - October 2011.
The correlation between the questionnaires was assessed using the Spearman’s
correlation coefficient. Results: Strong correlations were found between EQ-5D
index / VAS score and QUALEFFO-41 total score (ρ = -0.73 and ρ = -0.57, p< 0.001,
respectively). The EQ-5D dimensions “Pain/discomfort”, “Mobility”, “Activities”,
“Anxiety/Depression” similar to QUALEFFO-41 dimensions “Pain”, “Physical func-
tion”, “Leisure, social activities”, “Mental function” were also strongly correlated
(ρ = 0.42, ρ = 0.76, ρ = 0.46 and ρ = 0.32, p< 0.001, respectively). ConClusions: Strong
correlations between similar dimensions of the compared questionnaires were
notified. Negative values of the Spearman’s correlation coefficient indicated that
total score of the QUALEFFO-41 were scored in the reverse order. There was only
one QUALEFFO-41 dimension (“General health perception”) that is not similar to
any of the EQ-5D dimensions. Although there was a strong correlation between
the total scores of compared questionnaires, the results of the EQ-5D question-
naire should be observed with caution, because it does not contain all important
dimensions that osteoporosis affects",
publisher = "Elsevier Inc.",
journal = "Value in Health",
title = "Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?",
volume = "16",
number = "7",
pages = "A601-A601",
doi = "10.1016/j.jval.2013.08.1704"
}

Tadić, I., Lakić, D., Odalović, M., Tasić, L., Vujasinović-Stupar, N., Stevanović, D., Petrova, G.,& Krajnović, D.. (2013). Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?. in Value in Health
Elsevier Inc.., 16(7), A601-A601.
https://doi.org/10.1016/j.jval.2013.08.1704

Tadić I, Lakić D, Odalović M, Tasić L, Vujasinović-Stupar N, Stevanović D, Petrova G, Krajnović D. Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?. in Value in Health. 2013;16(7):A601-A601.
doi:10.1016/j.jval.2013.08.1704 .

Tadić, Ivana, Lakić, Dragana, Odalović, Marina, Tasić, Ljiljana, Vujasinović-Stupar, Nada, Stevanović, Dejan, Petrova, Guenka, Krajnović, Dušanka, "Can we use the eq-5d only for assessing the quality of life of patients with osteoporosis?" in Value in Health, 16, no. 7 (2013):A601-A601,
https://doi.org/10.1016/j.jval.2013.08.1704 . .

TY  - GEN
AU  - Tadić, Ivana
AU  - Vujasinović Stupar, Nada
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4219
AB  - Subjektivna merenja zdravlja, kao što je merenje kvaliteta života se fokusiraju na proceni uticaja bolesti i terapije na život pojedinaca. U cilju sticanja celokupne slike lečenja pacijenata i uspešnosti terapije, neophodno je da se pored kliničkih parametara prate i ekonomski i humanistički ishodi lečenja. Mnogim studijama je pokazano da se kvalitet života pacijenata sa dijagnozom osteoporoze razlikuje u zavisnosti od postojanja osteoporotične frakture, mesta nastanka frakture i broja fraktura. Domeni kvaliteta života koji su najčešće pogoršani usled bolesti jesu bol, nemogućnost obavljanja kućnih poslova, umanjena mogućnost fizičkog funkcionisanja, društvena izolacija, anksioznost, depresija, osećaj gubitka samopouzdanja i smanjene energije. Procena kvaliteta života pacijenata može da pomogne u izboru adekvatne terapije i omogući procenu efikasnosti terapije. Vrednosti kvaliteta života, ukoliko se praćenje izvrši u određenom vremenskom periodu, mogu da ukažu na efikasnost jednog leka, da omoguće poređenje efikasnosti dva ili više leka, ili da ukažu na bolju adherencu pacijenata kada se poredi upotreba više lekova. Merenje kvaliteta života omogućuje primenu farmakoekonomskih metoda koje se baziraju na poređenju troškova tokom terapije i promena u kvalitetu života pacijenata tokom lečenja. Budući da je osteoporoza hronična bolest, neophodan je multidiciplinaran pristup u lečenju. Razumevanje socijalnih dimenzija povezanih sa lečenjem bolesti je od velike važnosti u izboru adekvatne terapije i nege pacijenata.
PB  - Udruženje banjskih i klimatskih mesta Republike Srbije
T2  - Balneoclimatologia
T1  - Značaj procene kvaliteta života pacijenata sa osteoporozom I prisutnim fakturama
VL  - 39
IS  - 1
SP  - 215
EP  - 225
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4219
ER  - 

@misc{
author = "Tadić, Ivana and Vujasinović Stupar, Nada",
year = "2013",
abstract = "Subjektivna merenja zdravlja, kao što je merenje kvaliteta života se fokusiraju na proceni uticaja bolesti i terapije na život pojedinaca. U cilju sticanja celokupne slike lečenja pacijenata i uspešnosti terapije, neophodno je da se pored kliničkih parametara prate i ekonomski i humanistički ishodi lečenja. Mnogim studijama je pokazano da se kvalitet života pacijenata sa dijagnozom osteoporoze razlikuje u zavisnosti od postojanja osteoporotične frakture, mesta nastanka frakture i broja fraktura. Domeni kvaliteta života koji su najčešće pogoršani usled bolesti jesu bol, nemogućnost obavljanja kućnih poslova, umanjena mogućnost fizičkog funkcionisanja, društvena izolacija, anksioznost, depresija, osećaj gubitka samopouzdanja i smanjene energije. Procena kvaliteta života pacijenata može da pomogne u izboru adekvatne terapije i omogući procenu efikasnosti terapije. Vrednosti kvaliteta života, ukoliko se praćenje izvrši u određenom vremenskom periodu, mogu da ukažu na efikasnost jednog leka, da omoguće poređenje efikasnosti dva ili više leka, ili da ukažu na bolju adherencu pacijenata kada se poredi upotreba više lekova. Merenje kvaliteta života omogućuje primenu farmakoekonomskih metoda koje se baziraju na poređenju troškova tokom terapije i promena u kvalitetu života pacijenata tokom lečenja. Budući da je osteoporoza hronična bolest, neophodan je multidiciplinaran pristup u lečenju. Razumevanje socijalnih dimenzija povezanih sa lečenjem bolesti je od velike važnosti u izboru adekvatne terapije i nege pacijenata.",
publisher = "Udruženje banjskih i klimatskih mesta Republike Srbije",
journal = "Balneoclimatologia",
title = "Značaj procene kvaliteta života pacijenata sa osteoporozom I prisutnim fakturama",
volume = "39",
number = "1",
pages = "215-225",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4219"
}

Tadić, I.,& Vujasinović Stupar, N.. (2013). Značaj procene kvaliteta života pacijenata sa osteoporozom I prisutnim fakturama. in Balneoclimatologia
Udruženje banjskih i klimatskih mesta Republike Srbije., 39(1), 215-225.
https://hdl.handle.net/21.15107/rcub_farfar_4219

Tadić I, Vujasinović Stupar N. Značaj procene kvaliteta života pacijenata sa osteoporozom I prisutnim fakturama. in Balneoclimatologia. 2013;39(1):215-225.
https://hdl.handle.net/21.15107/rcub_farfar_4219 .

Tadić, Ivana, Vujasinović Stupar, Nada, "Značaj procene kvaliteta života pacijenata sa osteoporozom I prisutnim fakturama" in Balneoclimatologia, 39, no. 1 (2013):215-225,
https://hdl.handle.net/21.15107/rcub_farfar_4219 .

TY  - CONF
AU  - Vujasinović Stupar, Nada
AU  - Tadić, Ivana
PY  - 2013
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4220
AB  - Kost je dinamično tkivo u kome se neprekidno odigrava proces remodeliranja koji podrazumeva ciklus resorpcije starog koštanog tkiva i njegove zamene novim. U osteoporozi dolazi do disbalansa ova dva procesa u pravcu povećane koštane resorpcije, što slabi snagu koštanog tkiva i povećava rizik za prelome. Farmakološka terapija odobrena za prevenciju i lečenje osteoporoze je predominantno bazirana na antiresorptivnim agensima (aminobisfosfonati, SERM, kalcitonin, denosumab i estrogeni sa ili bez progesterona) različitog mehanizma dejstva. 
Aminobisfosfonati su najčešće prepisivani lekovi za ovu indikciju. Pokazano je da svi bisfosfonati redukuju vertebralne prelome. Osim sličnosti, bisfosfonati se međusobno razlikuju po 3D strukturi, afinitetu kojim se vezuju za koštani mineralni matriks, po farmakološkoj jačini i dužini supresije. Čini se da je glavni mehanizam kojim lekovi ove klase deluju, inhibicija ključnog enzima mevalonatnog puta (farnesil pirofosfataze) u osteoklastima, što indukuje njihovu apoptozu. Zbog akumulacije u kosti, bisfosfonati nastavljaju da se oslobađaju iz kosti godinama posle prestanka lečenja i njihova zaštita od preloma se produžava 3-5 godina po prestanku lečenja.
Novi agens denosumab je humano monoklonsko antitelo koje inhibira aktivnost liganda za receptor aktivator NFkB (RANKL), glavnog stimulatora stvaranja i aktivacije osteoklasta.   
Dok vodiči pružaju dobre smernice koji bolesnici treba da dobiju anti osteoporotičnu terapiju, oni ne daju specifične preporuke lekaru koji lek treba da prepiše u kojoj situaciji. Odabir leka u lečenju osteoporoze mora da bude  individualizovan za svakog pojedinačnog bolesnika. Da bi se odabrao najbolji lek za pojedinačnog bolesnika, lekar u dogovoru sa bolesnikom mora da razmotri nekoliko važnih osobina svake terapijske mogućnosti: efikasnost, sigurnost, cenu, pogodnost primene (dozni režim i način primene), ali i druge moguće ekstraskeletne koristi od antiosteoporotične terapije, koja nije direktno povezana sa osteoporozom (napr. bol, redukcija relativnost rizika za karcinom dojke).
PB  - Udruženje banjskih i klimatskih mesta Republike Srbije
C3  - Balneoclimatologia
T1  - Antiresorptivna terapija osteoporoze
VL  - 39
IS  - 1
SP  - 79
EP  - 94
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4220
ER  - 

@conference{
author = "Vujasinović Stupar, Nada and Tadić, Ivana",
year = "2013",
abstract = "Kost je dinamično tkivo u kome se neprekidno odigrava proces remodeliranja koji podrazumeva ciklus resorpcije starog koštanog tkiva i njegove zamene novim. U osteoporozi dolazi do disbalansa ova dva procesa u pravcu povećane koštane resorpcije, što slabi snagu koštanog tkiva i povećava rizik za prelome. Farmakološka terapija odobrena za prevenciju i lečenje osteoporoze je predominantno bazirana na antiresorptivnim agensima (aminobisfosfonati, SERM, kalcitonin, denosumab i estrogeni sa ili bez progesterona) različitog mehanizma dejstva. 
Aminobisfosfonati su najčešće prepisivani lekovi za ovu indikciju. Pokazano je da svi bisfosfonati redukuju vertebralne prelome. Osim sličnosti, bisfosfonati se međusobno razlikuju po 3D strukturi, afinitetu kojim se vezuju za koštani mineralni matriks, po farmakološkoj jačini i dužini supresije. Čini se da je glavni mehanizam kojim lekovi ove klase deluju, inhibicija ključnog enzima mevalonatnog puta (farnesil pirofosfataze) u osteoklastima, što indukuje njihovu apoptozu. Zbog akumulacije u kosti, bisfosfonati nastavljaju da se oslobađaju iz kosti godinama posle prestanka lečenja i njihova zaštita od preloma se produžava 3-5 godina po prestanku lečenja.
Novi agens denosumab je humano monoklonsko antitelo koje inhibira aktivnost liganda za receptor aktivator NFkB (RANKL), glavnog stimulatora stvaranja i aktivacije osteoklasta.   
Dok vodiči pružaju dobre smernice koji bolesnici treba da dobiju anti osteoporotičnu terapiju, oni ne daju specifične preporuke lekaru koji lek treba da prepiše u kojoj situaciji. Odabir leka u lečenju osteoporoze mora da bude  individualizovan za svakog pojedinačnog bolesnika. Da bi se odabrao najbolji lek za pojedinačnog bolesnika, lekar u dogovoru sa bolesnikom mora da razmotri nekoliko važnih osobina svake terapijske mogućnosti: efikasnost, sigurnost, cenu, pogodnost primene (dozni režim i način primene), ali i druge moguće ekstraskeletne koristi od antiosteoporotične terapije, koja nije direktno povezana sa osteoporozom (napr. bol, redukcija relativnost rizika za karcinom dojke).",
publisher = "Udruženje banjskih i klimatskih mesta Republike Srbije",
journal = "Balneoclimatologia",
title = "Antiresorptivna terapija osteoporoze",
volume = "39",
number = "1",
pages = "79-94",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4220"
}

Vujasinović Stupar, N.,& Tadić, I.. (2013). Antiresorptivna terapija osteoporoze. in Balneoclimatologia
Udruženje banjskih i klimatskih mesta Republike Srbije., 39(1), 79-94.
https://hdl.handle.net/21.15107/rcub_farfar_4220

Vujasinović Stupar N, Tadić I. Antiresorptivna terapija osteoporoze. in Balneoclimatologia. 2013;39(1):79-94.
https://hdl.handle.net/21.15107/rcub_farfar_4220 .

Vujasinović Stupar, Nada, Tadić, Ivana, "Antiresorptivna terapija osteoporoze" in Balneoclimatologia, 39, no. 1 (2013):79-94,
https://hdl.handle.net/21.15107/rcub_farfar_4220 .

TY  - CONF
AU  - Tadić, Ivana
AU  - Stevanović, Dejan
AU  - Tasić, Ljiljana
AU  - Vujasinović Stupar, Nada
AU  - Ljubišić, Danijela
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4233
AB  - Uvod: Prevalenca osteoporoze u poslednjoj deceniji je povećana. Bolje poznavanje osteoporoze postiže se adekvatanim načinom edukacije čime se podstiče razvoj preventivnog ponašanja, smanjenje faktora rizika za nastanak osteoporoze i poboljšanje saradnje pacijenata tokom lečenja. 
Cilj: Praćenje karakteristika srpske verzije upitnika za procenu znanja o osteoporozi (eng. The Serbian Version of the Osteoporosis Knowledge Assessment Tool – OKAT-S) u populaciji žena Srbije.
Metodologija: U istraživanju su učestvovale ispitanice ženskog pola. Istraživanje je sprovedeno u 23 zdravstvene ustanove u Srbiji tokom 2011. godine. Za potrebe ovog istraživanja korišćena je validirana verzija OKAT-S upitnika. Ovaj upitnik čini 9 izjava (pitanja) na koja su ponuđena tri odgovora: tačno, netačno i ne znam.
Rezultati: U istraživanju je učestvovalo 495 žena, prosečne starosti 43,53 godina (SD=11,43 godina). Vrednost koeficijenta unutrašnje konzistencije upitnika, tzv. Cronbach α iznosio je 0,65. Sva pitanja u upitniku bila su u odgovarajućem opsegu težine pitanja (od 0,22 do 0,68). Najniže vrednosti indeksa težine zabeležena su kod dva pitanja koja su se odnosila na definiciju osteoporoze i razvoj osteoporoze, dok je najviša vrednost zabeležena za pitanje koje se odnosilo na rizičnu populaciju, što se poklapa i sa zastupljenošću tačnih odgovora. Nešto manje od polovine žena (46,46%)  tačno je odgovorilo na više od polovine pitanja.
Zaključak: Upitnik OKAT-S je dobro prihvaćen u ispitivanoj populaciji žena Srbije. Upitnik je kratak i lako primenljiv u zdravstvenim ustanovama. Kako je poznavanje faktora rizika za razvoj osteoporoze promenljivo, upitnik OKAT-S predstavlja dobar instrument za prepoznavanje rizične populacije kojima je potrebna dodatna edukacija o ovoj bolesti, i kod koje postoje potrebe za razvojem preventivnog ponašanja i životnih navika.
PB  - Beograd: Farmaceutski fakultet Univerziteta u Beogradu
C3  - Zbornik radova simpozijuma "Zdravstveni ishodi & socijalna farmacija" / II naučni simpozijum Farmaceutskog fakulteta, 14. septembar 2012
T1  - Primena srpske verzije upitnika za procenu znanja o osteoporozi
SP  - 108
EP  - 109
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4233
ER  - 

@conference{
author = "Tadić, Ivana and Stevanović, Dejan and Tasić, Ljiljana and Vujasinović Stupar, Nada and Ljubišić, Danijela",
year = "2012",
abstract = "Uvod: Prevalenca osteoporoze u poslednjoj deceniji je povećana. Bolje poznavanje osteoporoze postiže se adekvatanim načinom edukacije čime se podstiče razvoj preventivnog ponašanja, smanjenje faktora rizika za nastanak osteoporoze i poboljšanje saradnje pacijenata tokom lečenja. 
Cilj: Praćenje karakteristika srpske verzije upitnika za procenu znanja o osteoporozi (eng. The Serbian Version of the Osteoporosis Knowledge Assessment Tool – OKAT-S) u populaciji žena Srbije.
Metodologija: U istraživanju su učestvovale ispitanice ženskog pola. Istraživanje je sprovedeno u 23 zdravstvene ustanove u Srbiji tokom 2011. godine. Za potrebe ovog istraživanja korišćena je validirana verzija OKAT-S upitnika. Ovaj upitnik čini 9 izjava (pitanja) na koja su ponuđena tri odgovora: tačno, netačno i ne znam.
Rezultati: U istraživanju je učestvovalo 495 žena, prosečne starosti 43,53 godina (SD=11,43 godina). Vrednost koeficijenta unutrašnje konzistencije upitnika, tzv. Cronbach α iznosio je 0,65. Sva pitanja u upitniku bila su u odgovarajućem opsegu težine pitanja (od 0,22 do 0,68). Najniže vrednosti indeksa težine zabeležena su kod dva pitanja koja su se odnosila na definiciju osteoporoze i razvoj osteoporoze, dok je najviša vrednost zabeležena za pitanje koje se odnosilo na rizičnu populaciju, što se poklapa i sa zastupljenošću tačnih odgovora. Nešto manje od polovine žena (46,46%)  tačno je odgovorilo na više od polovine pitanja.
Zaključak: Upitnik OKAT-S je dobro prihvaćen u ispitivanoj populaciji žena Srbije. Upitnik je kratak i lako primenljiv u zdravstvenim ustanovama. Kako je poznavanje faktora rizika za razvoj osteoporoze promenljivo, upitnik OKAT-S predstavlja dobar instrument za prepoznavanje rizične populacije kojima je potrebna dodatna edukacija o ovoj bolesti, i kod koje postoje potrebe za razvojem preventivnog ponašanja i životnih navika.",
publisher = "Beograd: Farmaceutski fakultet Univerziteta u Beogradu",
journal = "Zbornik radova simpozijuma "Zdravstveni ishodi & socijalna farmacija" / II naučni simpozijum Farmaceutskog fakulteta, 14. septembar 2012",
title = "Primena srpske verzije upitnika za procenu znanja o osteoporozi",
pages = "108-109",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4233"
}

Tadić, I., Stevanović, D., Tasić, L., Vujasinović Stupar, N.,& Ljubišić, D.. (2012). Primena srpske verzije upitnika za procenu znanja o osteoporozi. in Zbornik radova simpozijuma "Zdravstveni ishodi & socijalna farmacija" / II naučni simpozijum Farmaceutskog fakulteta, 14. septembar 2012
Beograd: Farmaceutski fakultet Univerziteta u Beogradu., 108-109.
https://hdl.handle.net/21.15107/rcub_farfar_4233

Tadić I, Stevanović D, Tasić L, Vujasinović Stupar N, Ljubišić D. Primena srpske verzije upitnika za procenu znanja o osteoporozi. in Zbornik radova simpozijuma "Zdravstveni ishodi & socijalna farmacija" / II naučni simpozijum Farmaceutskog fakulteta, 14. septembar 2012. 2012;:108-109.
https://hdl.handle.net/21.15107/rcub_farfar_4233 .

Tadić, Ivana, Stevanović, Dejan, Tasić, Ljiljana, Vujasinović Stupar, Nada, Ljubišić, Danijela, "Primena srpske verzije upitnika za procenu znanja o osteoporozi" in Zbornik radova simpozijuma "Zdravstveni ishodi & socijalna farmacija" / II naučni simpozijum Farmaceutskog fakulteta, 14. septembar 2012 (2012):108-109,
https://hdl.handle.net/21.15107/rcub_farfar_4233 .

TY  - CONF
AU  - Tadić, Ivana
AU  - Vujasinović-Stupar, Nada
AU  - Stevanović, Dejan
AU  - Tasić, Ljiljana
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1650
PB  - Springer
C3  - Osteoporosis International
T1  - Vertebral fractures and quality of life in osteoporotic patients
VL  - 23, Suppl. 2
SP  - S279
EP  - S279
DO  - 10.1007/s00198-012-1928-7
ER  - 

@conference{
author = "Tadić, Ivana and Vujasinović-Stupar, Nada and Stevanović, Dejan and Tasić, Ljiljana",
year = "2012",
publisher = "Springer",
journal = "Osteoporosis International",
title = "Vertebral fractures and quality of life in osteoporotic patients",
volume = "23, Suppl. 2",
pages = "S279-S279",
doi = "10.1007/s00198-012-1928-7"
}

Tadić, I., Vujasinović-Stupar, N., Stevanović, D.,& Tasić, L.. (2012). Vertebral fractures and quality of life in osteoporotic patients. in Osteoporosis International
Springer., 23, Suppl. 2, S279-S279.
https://doi.org/10.1007/s00198-012-1928-7

Tadić I, Vujasinović-Stupar N, Stevanović D, Tasić L. Vertebral fractures and quality of life in osteoporotic patients. in Osteoporosis International. 2012;23, Suppl. 2:S279-S279.
doi:10.1007/s00198-012-1928-7 .

Tadić, Ivana, Vujasinović-Stupar, Nada, Stevanović, Dejan, Tasić, Ljiljana, "Vertebral fractures and quality of life in osteoporotic patients" in Osteoporosis International, 23, Suppl. 2 (2012):S279-S279,
https://doi.org/10.1007/s00198-012-1928-7 . .

TY  - JOUR
AU  - Tadić, Ivana
AU  - Stevanović, Dejan
AU  - Tasić, Ljiljana
AU  - Vujasinović-Stupar, Nada
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1708
AB  - The aim of the authors of this study was to develop a short version of the Osteoporosis Knowledge Assessment Tool to be used for the target population of young adult Serbian females as an easily implemented add-on questionnaire. The 20-item Osteoporosis Knowledge Assessment Tool was translated and culturally adapted using the Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes Measures. The validation study was conducted on a sample of 250 female students studying at the Faculty of Pharmacy at the University of Belgrade, during a two-month period (November-December 2010). The difficulty index, item-total correlations, and internal consistency were calculated first. Afterward, confirmatory factor analysis was applied to test the structure of the Osteoporosis Knowledge Assessment Tool models and develop a short version. The mean total Osteoporosis Knowledge Assessment Tool score was 8.31 (possible range 0-20). The confirmatory factor analysis fit indices indicated poor fit of the data to the originally hypothesized structure. The confirmatory factor analysis fit indices, difficulty indices, and content validity allowed trimming of the original model and development of a short version with nine items. The average chi-square value for the Osteoporosis Knowledge Assessment Tool short version was 31.79 (p = 0.240, SE = 0.176) with Bollen-Stine bootstrap p = 0.249, Tucker-Lewis Index = 0.925, Comparative Fit Index = 0.944 and Root Mean Square Error of Approximation = 0.027. The Osteoporosis Knowledge Assessment Tool thus had acceptable characteristics and may be used for osteoporosis knowledge assessment.
PB  - Routledge Journals, Taylor & Francis Ltd
T2  - Women and Birth
T1  - Development of a Shorter Version of the Osteoporosis Knowledge Assessment Tool
VL  - 52
IS  - 1
SP  - 18
EP  - 31
DO  - 10.1080/03630242.2011.635246
ER  - 

@article{
author = "Tadić, Ivana and Stevanović, Dejan and Tasić, Ljiljana and Vujasinović-Stupar, Nada",
year = "2012",
abstract = "The aim of the authors of this study was to develop a short version of the Osteoporosis Knowledge Assessment Tool to be used for the target population of young adult Serbian females as an easily implemented add-on questionnaire. The 20-item Osteoporosis Knowledge Assessment Tool was translated and culturally adapted using the Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes Measures. The validation study was conducted on a sample of 250 female students studying at the Faculty of Pharmacy at the University of Belgrade, during a two-month period (November-December 2010). The difficulty index, item-total correlations, and internal consistency were calculated first. Afterward, confirmatory factor analysis was applied to test the structure of the Osteoporosis Knowledge Assessment Tool models and develop a short version. The mean total Osteoporosis Knowledge Assessment Tool score was 8.31 (possible range 0-20). The confirmatory factor analysis fit indices indicated poor fit of the data to the originally hypothesized structure. The confirmatory factor analysis fit indices, difficulty indices, and content validity allowed trimming of the original model and development of a short version with nine items. The average chi-square value for the Osteoporosis Knowledge Assessment Tool short version was 31.79 (p = 0.240, SE = 0.176) with Bollen-Stine bootstrap p = 0.249, Tucker-Lewis Index = 0.925, Comparative Fit Index = 0.944 and Root Mean Square Error of Approximation = 0.027. The Osteoporosis Knowledge Assessment Tool thus had acceptable characteristics and may be used for osteoporosis knowledge assessment.",
publisher = "Routledge Journals, Taylor & Francis Ltd",
journal = "Women and Birth",
title = "Development of a Shorter Version of the Osteoporosis Knowledge Assessment Tool",
volume = "52",
number = "1",
pages = "18-31",
doi = "10.1080/03630242.2011.635246"
}

Tadić, I., Stevanović, D., Tasić, L.,& Vujasinović-Stupar, N.. (2012). Development of a Shorter Version of the Osteoporosis Knowledge Assessment Tool. in Women and Birth
Routledge Journals, Taylor & Francis Ltd., 52(1), 18-31.
https://doi.org/10.1080/03630242.2011.635246

Tadić I, Stevanović D, Tasić L, Vujasinović-Stupar N. Development of a Shorter Version of the Osteoporosis Knowledge Assessment Tool. in Women and Birth. 2012;52(1):18-31.
doi:10.1080/03630242.2011.635246 .

Tadić, Ivana, Stevanović, Dejan, Tasić, Ljiljana, Vujasinović-Stupar, Nada, "Development of a Shorter Version of the Osteoporosis Knowledge Assessment Tool" in Women and Birth, 52, no. 1 (2012):18-31,
https://doi.org/10.1080/03630242.2011.635246 . .

TY  - JOUR
AU  - Tadić, Ivana
AU  - Vujasinović-Stupar, Nada
AU  - Tasić, Ljiljana
AU  - Stevanović, Dejan
AU  - Dimić, Aleksandar
AU  - Stamenković, Bojana
AU  - Stojanović, Sonja
AU  - Milenković, Sasa
PY  - 2012
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1622
AB  - Background: Vertebral fractures could lead to reduced physical, social and mental functioning, and loss of personal independence. Therefore, during the treatment of osteoporosis, it has become necessary to examine the changes in everyday functioning, well-being and health related quality of life (HRQOL). To that effect, this study aims to translate, culturally adapt, and validate the Serbian version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41) for patients with vertebral fractures. Methods: Nine female patients with osteoporosis participated in the pre-validation study. A validation, case-control study included two groups of female patients: one that consisted of 50 female patients with osteoporosis, and with at least one vertebral fracture, and another one that consisted of 50 control patients with osteoporosis but without fractures. They completed the QUALEFFO-41 and the EuroQol group questionnaire with five dimensions (EQ-5D) twice within a month. The validation study examined internal consistency, concurrent validity, test-retest reliability, sensitivity and specificity. Results: During the pre-validation study, three of the items in the QUALEFFO-41 were slightly changed. Afterwards, during the validation study, the statistically significant differences (adjusted for: age, duration of menopause, current employment and marital status) in the mean values of all domains and total scores between the groups were noted. For the case group, the internal consistency of the QUALEFFO-41 domains and of total questionnaire was above 0.70. The test-retest reliability was tested by the intraclass correlation coefficients (ICC) that were in range 0.87 - 0.96 for the case, and 0.15 - 0.83 for the control group. Correlations between the total scores of the QUALEFFO-41 and the EQ-5D health state value, for both groups were negative and statistically significant (r = -0.78, p lt 0.001 and r = -0.73, p lt 0.001, respectively). The QUALEFFO-41 had a better prediction of the value of HRQOL of cases compared to the generic questionnaire EQ-5D (the AUC difference was 0.099, p = 0.013). Conclusions: The Serbian QUALEFFO-41 version is reliable, valid, sensitive and predictive for examinations of HRQOL in patients with prevalent vertebral fractures and can be used in further studies.
PB  - Biomed Central Ltd, London
T2  - Health and Quality of Life Outcomes
T1  - Validation of the osteoporosis quality of life questionnaire QUALEFFO-41 for the Serbian population
VL  - 10
DO  - 10.1186/1477-7525-10-74
ER  - 

@article{
author = "Tadić, Ivana and Vujasinović-Stupar, Nada and Tasić, Ljiljana and Stevanović, Dejan and Dimić, Aleksandar and Stamenković, Bojana and Stojanović, Sonja and Milenković, Sasa",
year = "2012",
abstract = "Background: Vertebral fractures could lead to reduced physical, social and mental functioning, and loss of personal independence. Therefore, during the treatment of osteoporosis, it has become necessary to examine the changes in everyday functioning, well-being and health related quality of life (HRQOL). To that effect, this study aims to translate, culturally adapt, and validate the Serbian version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-41) for patients with vertebral fractures. Methods: Nine female patients with osteoporosis participated in the pre-validation study. A validation, case-control study included two groups of female patients: one that consisted of 50 female patients with osteoporosis, and with at least one vertebral fracture, and another one that consisted of 50 control patients with osteoporosis but without fractures. They completed the QUALEFFO-41 and the EuroQol group questionnaire with five dimensions (EQ-5D) twice within a month. The validation study examined internal consistency, concurrent validity, test-retest reliability, sensitivity and specificity. Results: During the pre-validation study, three of the items in the QUALEFFO-41 were slightly changed. Afterwards, during the validation study, the statistically significant differences (adjusted for: age, duration of menopause, current employment and marital status) in the mean values of all domains and total scores between the groups were noted. For the case group, the internal consistency of the QUALEFFO-41 domains and of total questionnaire was above 0.70. The test-retest reliability was tested by the intraclass correlation coefficients (ICC) that were in range 0.87 - 0.96 for the case, and 0.15 - 0.83 for the control group. Correlations between the total scores of the QUALEFFO-41 and the EQ-5D health state value, for both groups were negative and statistically significant (r = -0.78, p lt 0.001 and r = -0.73, p lt 0.001, respectively). The QUALEFFO-41 had a better prediction of the value of HRQOL of cases compared to the generic questionnaire EQ-5D (the AUC difference was 0.099, p = 0.013). Conclusions: The Serbian QUALEFFO-41 version is reliable, valid, sensitive and predictive for examinations of HRQOL in patients with prevalent vertebral fractures and can be used in further studies.",
publisher = "Biomed Central Ltd, London",
journal = "Health and Quality of Life Outcomes",
title = "Validation of the osteoporosis quality of life questionnaire QUALEFFO-41 for the Serbian population",
volume = "10",
doi = "10.1186/1477-7525-10-74"
}

Tadić, I., Vujasinović-Stupar, N., Tasić, L., Stevanović, D., Dimić, A., Stamenković, B., Stojanović, S.,& Milenković, S.. (2012). Validation of the osteoporosis quality of life questionnaire QUALEFFO-41 for the Serbian population. in Health and Quality of Life Outcomes
Biomed Central Ltd, London., 10.
https://doi.org/10.1186/1477-7525-10-74

Tadić I, Vujasinović-Stupar N, Tasić L, Stevanović D, Dimić A, Stamenković B, Stojanović S, Milenković S. Validation of the osteoporosis quality of life questionnaire QUALEFFO-41 for the Serbian population. in Health and Quality of Life Outcomes. 2012;10.
doi:10.1186/1477-7525-10-74 .

Tadić, Ivana, Vujasinović-Stupar, Nada, Tasić, Ljiljana, Stevanović, Dejan, Dimić, Aleksandar, Stamenković, Bojana, Stojanović, Sonja, Milenković, Sasa, "Validation of the osteoporosis quality of life questionnaire QUALEFFO-41 for the Serbian population" in Health and Quality of Life Outcomes, 10 (2012),
https://doi.org/10.1186/1477-7525-10-74 . .

TY  - CHAP
AU  - Vujasinović Stupar, Nada
AU  - Tadić, Ivana
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4213
PB  - Beograd : Medicinski fakultet : Udruženje za preventivu i lečenje osteoporoze u Srbiji (UPLOS)
T2  - Osteopenija
T1  - Osteopenija-značaj i mogućnost prevencije
SP  - 295
EP  - 311
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4213
ER  - 

@inbook{
author = "Vujasinović Stupar, Nada and Tadić, Ivana",
year = "2010",
publisher = "Beograd : Medicinski fakultet : Udruženje za preventivu i lečenje osteoporoze u Srbiji (UPLOS)",
journal = "Osteopenija",
booktitle = "Osteopenija-značaj i mogućnost prevencije",
pages = "295-311",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4213"
}

Vujasinović Stupar, N.,& Tadić, I.. (2010). Osteopenija-značaj i mogućnost prevencije. in Osteopenija
Beograd : Medicinski fakultet : Udruženje za preventivu i lečenje osteoporoze u Srbiji (UPLOS)., 295-311.
https://hdl.handle.net/21.15107/rcub_farfar_4213

Vujasinović Stupar N, Tadić I. Osteopenija-značaj i mogućnost prevencije. in Osteopenija. 2010;:295-311.
https://hdl.handle.net/21.15107/rcub_farfar_4213 .

Vujasinović Stupar, Nada, Tadić, Ivana, "Osteopenija-značaj i mogućnost prevencije" in Osteopenija (2010):295-311,
https://hdl.handle.net/21.15107/rcub_farfar_4213 .

TY  - CHAP
AU  - Lakić, Dragana
AU  - Tadić, Ivana
AU  - Vujasinović Stupar, Nada
AU  - Tasić, Ljiljana
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4214
AB  - Остеопороза је хронична, прогресивна болест која представља оптерећење за пацијента и друштво; за пацијента у смислу квалитета живота, а за друштво у смислу економског оптерећења које ова болест носи. Фармакоекономија омогућава одређивање адекватног односа трошак/корист и правилно распоређивање ограничених новчаних средстава. Олакшана могућност за постављање дијагнозе остеопорозе мерењем коштане масе, довела је до појаве великог броја болесница са овом дијагнозом. Циљ превенције и терапије остеопорозе је смањење ризика од прелома. У Србији је највећа инциденција прелома регистрована код старијих од 80 година (847,9 /100 000 становника). Трошкови лечења прелома у Сједињеним Америчким Државама у 2005. години износили су 16,7 милијарди долара, при чему 57% ових средстава одлази на трошкове болничког лечења. За фармакоекономске евалуације терапије остеопорозе углавном се користи референтни
Марковљев модел. Резултат фармакоекономске анализе остеопорозе већином се изражава као однос трошкова и година живота коригованим у односу на квалитет живота (quality adjusted life year, QALY). Скорашње економске анализе одражавају став о ограниченој примени хормонске субституционе терапије, као и проширивању области истраживања на мушку популацију.
AB  - Osteoporosis is a chronic, degenerative disease presenting a burden for patients and society; for patients in terms of reduction in life quality, and for society in terms of economic burden. Pharmacoeconomics provide the assessment of acceptable ratio between costs and benefits, and the adequate allocation of limited monetary resources. The easier diagnosis of osteoporosis using the bone densitometry, had led to the increase in the number of female patients with this diagnosis. The aim of prevention and therapy of osteoporosis is to reduce the risk of fractures. The incidence of fracture in Serbia is the highest among persons older than 80 years (847.9/100 000 inhabitants).
Expenditures for fracture therapy in USA in year 2005 were USD 16.7 billions, with 57% allocated
on cost for hospitalization. For the pharmacoeconomic evaluations of osteoporosis therapy is widely used referent Markov model. The result of pharmacoeconomic osteoporosis evaluation is usually expressed as cost per quality adjusted life year, QALY. Recent pharmacoeconomic studies reflect the position of limited usage of hormone replacement therapy, and broadening of the research into male population.
PB  - Београд : Универзитет, Фармацеутски факултет
T2  - Здравље жена у Србији : промоција здравља, превенција болести и терапија
T1  - Osteoproza i farmakoekonomski aspekti
VL  - 328
SP  - 313
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4214
ER  - 

@inbook{
author = "Lakić, Dragana and Tadić, Ivana and Vujasinović Stupar, Nada and Tasić, Ljiljana",
year = "2009",
abstract = "Остеопороза је хронична, прогресивна болест која представља оптерећење за пацијента и друштво; за пацијента у смислу квалитета живота, а за друштво у смислу економског оптерећења које ова болест носи. Фармакоекономија омогућава одређивање адекватног односа трошак/корист и правилно распоређивање ограничених новчаних средстава. Олакшана могућност за постављање дијагнозе остеопорозе мерењем коштане масе, довела је до појаве великог броја болесница са овом дијагнозом. Циљ превенције и терапије остеопорозе је смањење ризика од прелома. У Србији је највећа инциденција прелома регистрована код старијих од 80 година (847,9 /100 000 становника). Трошкови лечења прелома у Сједињеним Америчким Државама у 2005. години износили су 16,7 милијарди долара, при чему 57% ових средстава одлази на трошкове болничког лечења. За фармакоекономске евалуације терапије остеопорозе углавном се користи референтни
Марковљев модел. Резултат фармакоекономске анализе остеопорозе већином се изражава као однос трошкова и година живота коригованим у односу на квалитет живота (quality adjusted life year, QALY). Скорашње економске анализе одражавају став о ограниченој примени хормонске субституционе терапије, као и проширивању области истраживања на мушку популацију., Osteoporosis is a chronic, degenerative disease presenting a burden for patients and society; for patients in terms of reduction in life quality, and for society in terms of economic burden. Pharmacoeconomics provide the assessment of acceptable ratio between costs and benefits, and the adequate allocation of limited monetary resources. The easier diagnosis of osteoporosis using the bone densitometry, had led to the increase in the number of female patients with this diagnosis. The aim of prevention and therapy of osteoporosis is to reduce the risk of fractures. The incidence of fracture in Serbia is the highest among persons older than 80 years (847.9/100 000 inhabitants).
Expenditures for fracture therapy in USA in year 2005 were USD 16.7 billions, with 57% allocated
on cost for hospitalization. For the pharmacoeconomic evaluations of osteoporosis therapy is widely used referent Markov model. The result of pharmacoeconomic osteoporosis evaluation is usually expressed as cost per quality adjusted life year, QALY. Recent pharmacoeconomic studies reflect the position of limited usage of hormone replacement therapy, and broadening of the research into male population.",
publisher = "Београд : Универзитет, Фармацеутски факултет",
journal = "Здравље жена у Србији : промоција здравља, превенција болести и терапија",
booktitle = "Osteoproza i farmakoekonomski aspekti",
volume = "328",
pages = "313",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4214"
}

Lakić, D., Tadić, I., Vujasinović Stupar, N.,& Tasić, L.. (2009). Osteoproza i farmakoekonomski aspekti. in Здравље жена у Србији : промоција здравља, превенција болести и терапија
Београд : Универзитет, Фармацеутски факултет., 328, 313.
https://hdl.handle.net/21.15107/rcub_farfar_4214

Lakić D, Tadić I, Vujasinović Stupar N, Tasić L. Osteoproza i farmakoekonomski aspekti. in Здравље жена у Србији : промоција здравља, превенција болести и терапија. 2009;328:313.
https://hdl.handle.net/21.15107/rcub_farfar_4214 .

Lakić, Dragana, Tadić, Ivana, Vujasinović Stupar, Nada, Tasić, Ljiljana, "Osteoproza i farmakoekonomski aspekti" in Здравље жена у Србији : промоција здравља, превенција болести и терапија, 328 (2009):313,
https://hdl.handle.net/21.15107/rcub_farfar_4214 .

TY  - CHAP
AU  - Vujasinović Stupar, Nada
AU  - Tadić, Ivana
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4215
AB  - Иако је остеопороза болест и жена и мушкараца, преваленција је већа код жена и повећава се у менопаузи. Према етиологији болести разликујемо примарну (идиопатску) и секундарну остеопорозу. Третман остеопорозе може се поделити на мере превенције и лечење специфичном фармакотерапијом. Разматрање улоге кофактора у процесу ремоделовања
костију олакшава разумевање механизма дејства дијететских намирница и лекова који се
могу користити у превенцији и/или терапији остеопорозе. Неопходно је да здравствени радници буду у потпуности упознати са предностима и ризицима при постављању
дијагнозе и лечењу остеопорозе.
AB  - Although osteoporosis affects both men and women, it is more prevalent among women and increases during menopause. Based on the etiology osteoporosis may be primary (idiopathic) or secondary. The treatment of osteoporosis is divided into the basic measures for fracture prevention and/or the specific pharmacotherapy. By understanding the role of cofactors in the processes of bone remodeling we can explain the mechanisms of action of dietary supplements and drugs which can be used in the prevention or treatment of osteoporosis. It is important for health care providers to be fully aware of the potential risks and benefits of diagnosis and treating osteoporosis.
PB  - Београд : Универзитет, Фармацеутски факултет.
T2  - Здравље жена у Србији : промоција здравља, превенција болести и терапија
T1  - Osteoporoza - prevencija i farmakoterapija
SP  - 295
EP  - 311
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4215
ER  - 

@inbook{
author = "Vujasinović Stupar, Nada and Tadić, Ivana",
year = "2009",
abstract = "Иако је остеопороза болест и жена и мушкараца, преваленција је већа код жена и повећава се у менопаузи. Према етиологији болести разликујемо примарну (идиопатску) и секундарну остеопорозу. Третман остеопорозе може се поделити на мере превенције и лечење специфичном фармакотерапијом. Разматрање улоге кофактора у процесу ремоделовања
костију олакшава разумевање механизма дејства дијететских намирница и лекова који се
могу користити у превенцији и/или терапији остеопорозе. Неопходно је да здравствени радници буду у потпуности упознати са предностима и ризицима при постављању
дијагнозе и лечењу остеопорозе., Although osteoporosis affects both men and women, it is more prevalent among women and increases during menopause. Based on the etiology osteoporosis may be primary (idiopathic) or secondary. The treatment of osteoporosis is divided into the basic measures for fracture prevention and/or the specific pharmacotherapy. By understanding the role of cofactors in the processes of bone remodeling we can explain the mechanisms of action of dietary supplements and drugs which can be used in the prevention or treatment of osteoporosis. It is important for health care providers to be fully aware of the potential risks and benefits of diagnosis and treating osteoporosis.",
publisher = "Београд : Универзитет, Фармацеутски факултет.",
journal = "Здравље жена у Србији : промоција здравља, превенција болести и терапија",
booktitle = "Osteoporoza - prevencija i farmakoterapija",
pages = "295-311",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4215"
}

Vujasinović Stupar, N.,& Tadić, I.. (2009). Osteoporoza - prevencija i farmakoterapija. in Здравље жена у Србији : промоција здравља, превенција болести и терапија
Београд : Универзитет, Фармацеутски факултет.., 295-311.
https://hdl.handle.net/21.15107/rcub_farfar_4215

Vujasinović Stupar N, Tadić I. Osteoporoza - prevencija i farmakoterapija. in Здравље жена у Србији : промоција здравља, превенција болести и терапија. 2009;:295-311.
https://hdl.handle.net/21.15107/rcub_farfar_4215 .

Vujasinović Stupar, Nada, Tadić, Ivana, "Osteoporoza - prevencija i farmakoterapija" in Здравље жена у Србији : промоција здравља, превенција болести и терапија (2009):295-311,
https://hdl.handle.net/21.15107/rcub_farfar_4215 .